Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

An Open-Label Expanded Access Protocol for Esketamine Treatment of Subjects With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives

To see complete record on, please visit this link

Id: NCT04476446

Organisation Name: Janssen-Cilag, S.A.

Overal Status: Recruiting

Start Date: September 8, 2020

Last Update: November 16, 2020

Lead Sponsor: Janssen-Cilag, S.A.

Brief Summary: The purpose of this expanded access program (EAP) is to provide expanded access to esketamine treatment and collect additional safety data and quality of life until esketamine is commercially available for participants with Treatment-Resistant Depression (TRD).

  • Depression

Total execution time in seconds: 0.15373587608337